Heilongjiang ZBD Pharmaceutical Co Ltd - Asset Resilience Ratio
Heilongjiang ZBD Pharmaceutical Co Ltd (603567) has an Asset Resilience Ratio of 0.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Heilongjiang ZBD Pharmaceutical Co Ltd (603567) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Heilongjiang ZBD Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See 603567 equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Heilongjiang ZBD Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Heilongjiang ZBD Pharmaceutical Co Ltd market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥463.76K | 0.0% |
| Total Liquid Assets | CN¥463.76K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Heilongjiang ZBD Pharmaceutical Co Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Heilongjiang ZBD Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Heilongjiang ZBD Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 0.76% |
|
Eris Lifesciences Limited
NSE:ERIS |
Drug Manufacturers - Specialty & Generic | 0.58% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Lotus Pharmaceutical Co Ltd
TW:1795 |
Drug Manufacturers - Specialty & Generic | 0.49% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC |
Drug Manufacturers - Specialty & Generic | 0.64% |
Annual Asset Resilience Ratio for Heilongjiang ZBD Pharmaceutical Co Ltd (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Heilongjiang ZBD Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | CN¥537.23K ≈ $78.61K |
CN¥12.71 Billion ≈ $1.86 Billion |
+0.00pp |
| 2023-12-31 | 0.00% | CN¥427.03K ≈ $62.49K |
CN¥12.47 Billion ≈ $1.82 Billion |
0.00pp |
| 2022-12-31 | 0.00% | CN¥505.09K ≈ $73.91K |
CN¥11.68 Billion ≈ $1.71 Billion |
-6.16pp |
| 2016-12-31 | 6.17% | CN¥396.00 Million ≈ $57.95 Million |
CN¥6.42 Billion ≈ $939.30 Million |
-- |
About Heilongjiang ZBD Pharmaceutical Co Ltd
Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in China. It offers cardiovascular and cerebrovascular, respiratory system, orthopedics, tumors, digestive system, anti-infection, mental nerve, genitourinary, and other disease fields. The company was founded in 1996 and is based in Hulin, China.